share_log

Oppenheimer Initiates Coverage On Entrada Therapeutics With Outperform Rating, Announces Price Target of $22

Benzinga ·  Jan 5 07:23

Oppenheimer analyst Hartaj Singh initiates coverage on Entrada Therapeutics (NASDAQ:TRDA) with a Outperform rating and announces Price Target of $22.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment